Sponsor or institution

Clinical trials and research at Keymed Biosciences Co.Ltd

• 14Clinical trials
• 1Country

Newest trials

All recruiting trials (14)

• Single-dose CM383 in healthy adult men

  This trial will test a single dose of CM383 given by IV infusion or subcutaneous injection in healthy adult men to see how the drug is processed, whether it triggers immune responses, and if it is safe.

  Recruiting Phase 1 Keymed Biosciences Co.Ltd · Hangzhou · NCT07292688

• Long-term safety and efficacy of CM512 for atopic dermatitis

  This open-label follow-up will test whether continuing CM512 is safe and helps people with atopic dermatitis who finished a parent CM512 study.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Beijing, Beijing Municipality · NCT07230483

• Single intravenous CM559 dosing in healthy adult men

  This trial tests single intravenous doses of CM559 to see if they are safe and how the drug is processed in healthy men aged 18–60.

  Recruiting Phase 1 Keymed Biosciences Co.Ltd · Chengdu, Sichuan · NCT07175506

• CM336 treatment for relapsed or refractory autoimmune cytopenia

  This trial will test whether CM336, a BCMA/CD3 bispecific antibody given by injection, can help adults with relapsed or refractory autoimmune cytopenias such as ITP, AIHA, or Evans syndrome.

  Recruiting at 3 sites Phase 1/2 Keymed Biosciences Co.Ltd · Zhengzhou, Henan and 2 other locations · NCT07175493

• CM512 injection for adults with chronic spontaneous urticaria

  This study will test whether injections of CM512 reduce hives and itching in adults with chronic spontaneous urticaria who still have symptoms despite second-generation H1‑antihistamines.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Tianjin, Tianjin Municipality · NCT07166211

• CM336 (BCMA/CD3 bispecific antibody) for adults with relapsed or refractory light-chain (AL) amyloidosis

  This will test whether CM336, a BCMA/CD3 bispecific antibody, helps adults with relapsed or refractory AL amyloidosis and is safe to use.

  Recruiting at 2 sites Phase 2 Keymed Biosciences Co.Ltd · Beijing, Beijing Municipality and 1 other locations · NCT07039578

• CM518D1 treatment for advanced solid tumors

  This trial will test CM518D1 to see if it is safe, tolerable, and can help adults with advanced solid tumors.

  Recruiting Phase 1/2 Keymed Biosciences Co.Ltd · Guangzhou, Guangdong · NCT07019779

• CM512 injection for adults with moderate-to-severe asthma

  This will test whether CM512 injections help adults with moderate-to-severe asthma control symptoms better than a placebo.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Guangzhou, Guangdong · NCT07011524

• CM512 for adults with moderate-to-severe atopic dermatitis

  This study will test whether CM512 helps adults with moderate-to-severe atopic dermatitis reduce itching and improve skin lesions compared with a placebo.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Beijing · NCT06947980

• CM313 (subcutaneous) injection for platelet transfusion refractoriness

  This trial tests whether a subcutaneous injection of CM313 can safely improve platelet transfusion responses in adults with immune-related platelet transfusion refractoriness.

  Recruiting Phase 1/2 Keymed Biosciences Co.Ltd · Tianjin, Tianjin Municipality · NCT06792019

• Evaluating CM383 for Mild Cognitive Impairment and Mild Alzheimer's Disease

  This study is testing a new medication called CM383 to see if it can help people with mild cognitive impairment and mild Alzheimer's disease feel better and improve their symptoms.

  Recruiting Phase 1 Keymed Biosciences Co.Ltd · Hefei · NCT06619613

• Treatment of IgA Nephropathy with CM338

  This study is testing a new treatment called CM338 to see if it can help people with IgA nephropathy manage their kidney disease better.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Beijing, Beijing Municipality · NCT05775042

• Evaluating CM336 for patients with relapsed or refractory multiple myeloma

  This study is testing a new treatment called CM336 to see if it can help people with relapsed or refractory multiple myeloma feel better and manage their disease.

  Recruiting Phase 1/2 Keymed Biosciences Co.Ltd · Beijing, Beijing Municipality · NCT05299424

• Evaluating CM350 for patients with advanced solid tumors

  This study is testing a new treatment called CM350 to see if it is safe and effective for people with advanced solid tumors that have a specific marker.

  Recruiting at 2 sites Phase 1/2 Keymed Biosciences Co.Ltd · Chengdu, Sichuan and 1 other locations · NCT05263960

Quick answers

How many clinical trials run by Keymed Biosciences Co.Ltd are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1/2: 5, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →